CD38 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy

This CD38 target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP. It turns target biology, disease context, clinical validation, competitive intensity, and IP strategy into a repeatable target evaluation workflow for life sciences AI agents.

Explore PatSnap Life Sciences MCP Servers

Target

CD38

UniProt P28907

Target-linked drugs

182

142 active development drugs

Multiple myeloma trials

397

CD38 + multiple myeloma MCP query

Released results

538

Clinical result query

Executive View

CD38 is a benchmark multiple myeloma target with extensive validation through daratumumab and isatuximab-centered regimens. The target remains valuable, but white space is concentrated in delivery convenience, subcutaneous administration, combination sequencing, and activity after prior CD38 exposure.

Biology: Target & Disease MCP identifies CD38 as a multifunctional transmembrane glycoprotein with enzymatic activity, calcium mobilization, signaling, and adhesion functions.
Disease context: Multiple myeloma is a mature plasma-cell malignancy with skeletal destruction, anemia, hypercalcemia, and renal insufficiency.
Validation: Clinical Trials MCP returns 397 CD38 + Multiple Myeloma trials and 538 released result records.
Strategy: Differentiate by delivery route, combination backbone, CD38 retreatment/post-exposure setting, and safety in older or transplant-ineligible patients.

Scorecard

Biology confidence: Very high

Clinical validation: Very high

Competitive pressure: Very high

White-space potential: Operational and sequencing-led

Biology and Disease Rationale

Target & Disease MCP returns CD38 with UniProt P28907, 182 target-linked drugs, and 142 active development drugs. The target profile describes CD38 as a multifunctional transmembrane glycoprotein involved in enzymatic activity, calcium mobilization, signaling, and ligand binding, providing a strong biological basis for antibody therapy in plasma-cell malignancy.

For multiple myeloma, Target & Disease MCP describes a malignancy of mature plasma cells involving monoclonal immunoglobulin production, skeletal destruction, bone pain, anemia, hypercalcemia, and renal insufficiency. The disease record shows 823 development drugs and 958 roll-up development drugs.

Explore PatSnap Life Sciences MCP Servers for AI agents

Selected Trial and Result Evidence

AZD4045 in R/R multiple myeloma
Clinical Trials MCP returned a not-yet-recruiting modular Phase 1/2 study in relapsed/refractory multiple myeloma.

TRIlogy-7 ramantamig plus daratumumab
Not-yet-recruiting Phase 3 study comparing ramantamig plus daratumumab versus established daratumumab-containing regimens in NDMM where transplant is not planned.

ISABELA combination study
Clinical trial result query returned a positive Phase 2 result for isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Daratumumab real-world comparison
Released positive real-world result comparing Dara-VRD, VRD, and Dara-RD in transplant-ineligible older adults with newly diagnosed multiple myeloma.

IP and R&D Recommendation

CD38 IP review should map antibody epitopes, Fc engineering, subcutaneous/on-body delivery, combination claims with proteasome inhibitors, IMiDs and BCMA agents, retreatment strategies, and use in transplant-ineligible or frail populations.

Recommendation

CD38 is highly validated but commercially crowded. New opportunities should be framed around better delivery, safer combination design, post-CD38-exposure efficacy, or practical advantages for older transplant-ineligible patients.

Start building target evaluation agents with PatSnap Life Sciences MCP Servers

Data note: Target biology, disease profile, clinical trial counts, trial examples, and result evidence were generated from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP queries performed on July 9, 2026.